Notable Labs

Notable Labs EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of Notable Labs (NTBLQ) as of Nov 20, 2026.

EV/EBIT

-0.00

YoY

124.12%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Notable Labs is 2023 -0.00 . EV/EBIT (Enterprise Value to EBIT) of Notable Labs was 2022 -0.00 . It decreases by 124.12% lower compared to the previous year.

The Notable Labs EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
0.00 USD
The Notable Labs EV/EBIT history
YEAREV/EBITYoY
est0.00—
est0.00-100.00%
-0.00+124.12%
-0.00-8.68%
-0.00-18.40%
-0.00-17.97%
-0.00+5.83%
-0.00-49.84%
-0.00+52.72%
-0.00-8.66%
-0.00-0.61%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Notable Labs's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Notable Labs's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Notable Labs's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Notable Labs grows earnings faster than its peers.

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Notable Labs

All Key Metrics — Notable Labs